Les publications

Page en cours de mise à jour... Retrouvez ici les publications des équipes de recherche du CGO

384 publications
Année de publication :
Réseaux :

African-specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer.

Polygenic hazard score (PHS) models are associated with age at diagnosis of prostate cancer. Our model developed in Europeans (PHS46) showed reduced performance in men with African genetic ancestry.

  • Ref: Int J Cancer. 2020 Sep 15.
  • Année de publication : 2020
  • Auteurs : Karunamuni RA, Huynh-Le MP, Fan CC, Thompson W, Eeles RA, Kote-Jarai Z, Muir K; UKGPCS Collaborators, Lophatananon A, Tangen CM, Goodman PJ, Thompson IM Jr, Blot WJ, Zheng W, Kibel AS, Drake BF, Cussenot O, Cancel-Tassin G, Menegaux F, Truong T, Park JY, Lin HY, Bensen JT, Fontham ETH, Mohler JL, Taylor JA, Multigner L, Blanchet P, Brureau L, Romana M, Leach RJ, John EM, Fowke J, Bush WS, Aldrich M, Crawford DC, Srivastava S, Cullen JC, Petrovics G, Parent MÉ, Hu JJ, Sanderson M, Mills IG, Andreassen OA, Dale AM, Seibert TM; PRACTICAL Consortium.
  • Réseaux : Réseaux: « Cancers des Tissus Hormono-dépendants »
Lire la publication

Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell…

Purpose: To evaluate first-line pembrolizumab monotherapy efficacy and safety in patients with unresectable cutaneous squamous cell carcinomas (CSCCs).

  • Ref: J Clin Oncol. 2020 Sep 10;38(26):3051-3061.
  • Année de publication : 2020
  • Auteurs : Maubec E, Boubaya M, Petrow P, Beylot-Barry M, Basset-Seguin N, Deschamps L, Grob JJ, Dréno B, Scheer- Senyarich I, Bloch-Queyrat C, Leccia MT, Stefan A, Saiag P, Grange F, Meyer N, de Quatrebarbes J, Dinulescu M, Legoupil D, Machet L, Dereure O, Zehou O, Montaudié H, Wierzbicka-Hainaut E, Le Corre Y, Mansard S, Guégan S, Arnault JP, Dalac S, Aubin F, Alloux C, Lopez I, Cherbal S, Tibi A, Lévy V.
  • Réseaux : Réseaux: non classé
Lire la publication

Management of Patients with Node-positive Prostate Cancer at Radical Prostatectomy and Pelvic Lymph Node Dissection.

Context: Optimal management of prostate cancer (PCa) patients with lymph node invasion at radical prostatectomy and pelvic lymph node dissection still remains unclear.

  • Ref: Eur Urol Oncol. 2020 Oct;3(5):565-581.
  • Année de publication : 2020
  • Auteurs : Marra G, Valerio M, Heidegger I, Tsaur I, Mathieu R, Ceci F, Ploussard G, van den Bergh RCN, Kretschmer A, Thibault C, Ost P, Tilki D, Kasivisvanathan V, Moschini M, Sanchez-Salas R, Gontero P, Karnes RJ, Montorsi F, Gandaglia G; EAU-YAU Prostate Cancer Working Party.
  • Réseaux : Réseaux: « Cancers des Tissus Hormono-dépendants »
Lire la publication

PTPN11 mutations in canine and human disseminated histiocytic sarcoma.

In humans, histiocytic sarcoma (HS) is an aggressive cancer involving histiocytes. Its rarity and heterogeneity explain that treatment remains a challenge.

  • Ref: Int J Cancer. 2020 Sep 15;147(6):1657-1665.
  • Année de publication : 2020
  • Auteurs : Hédan B, Rault M, Abadie J, Ulvé R, Botherel N, Devauchelle P, Copie-Bergman C, Cadieu E, Parrens M, Alten J, Zalcman EL, Cario G, Damaj G, Mokhtari K, Le Loarer F, Coulomb-Lhermine A, Derrien T, Hitte C, Bachelot L, Breen M, Gilot D, Blay JY, Donadieu J, André C.
  • Réseaux : Réseaux: « Vectorisation, Imagerie, Radiothérapies »
Lire la publication

Overall survival among chemotherapy-naïve castration-resistant prostate cancer patients under abiraterone versus enzalutamide.

Abiraterone acetate (ABI) and enzalutamide (ENZ) are considered to be clinically relevant comparators among chemotherapy-naive patients with castration-resistant prostate cancer.

  • Ref: Am J Epidemiol. 2020 Sep 18:kwaa190.
  • Année de publication : 2020
  • Auteurs : Scailteux LM, Campillo-Gimenez B, Kerbrat S, Despas F, Mathieu R, Vincendeau S, Balusson F, Happe A, Nowak E, Oger E.
  • Réseaux : Réseaux: « Cancers des Tissus Hormono-dépendants »
Lire la publication

A Germline Variant at 8q24 Contributes to Familial Clustering of Prostate Cancer in Men of African…

Although men of African ancestry have a high risk of prostate cancer (PCa), no genes or mutations have been identified that contribute to familial clustering of PCa in this population.

  • Ref: Eur Urol. 2020 Sep;78(3):316-320.
  • Année de publication : 2020
  • Auteurs : Darst BF, Wan P, Sheng X, Bensen JT, Ingles SA, Rybicki BA, Nemesure B, John EM, Fowke JH, Stevens VL, Berndt SI, Huff CD, Strom SS, Park JY, Zheng W, Ostrander EA, Walsh PC, Srivastava S, Carpten J, Sellers TA, Yamoah K, Murphy AB, Sanderson M, Crawford DC, Gapstur SM, Aldrich MC, Cussenot O, Yeager M, Petrovics G, Cullen J, Neslund-Dudas C, Kittles RA, Xu J, Stern MC, Kote-Jarai Z, Govindasami K, Chokkalingam AP, Multigner L, Parent ME, Menegaux F, Cancel-Tassin G, Kibel AS, Klein EA, Goodman PJ, Drake BF, Hu JJ, Clark PE, Blanchet P, Casey G, Hennis AJM, Lubwama A, Thompson IM Jr, Leach R, Gundell SM, Pooler L, Xia L, Mohler JL, Fontham ETH, Smith GJ, Taylor JA, Eeles RA, Brureau L, Chanock SJ, Watya S, Stanford JL, Mandal D, Isaacs WB, Cooney K, Blot WJ, Conti DV, Haiman CA.
  • Réseaux : Réseaux: non classé
Lire la publication

Planning With Patient-Specific Rectal Sub-Region Constraints Decreases Probability of Toxicity in Prostate Cancer Radiotherapy.

Background: A rectal sub-region (SRR) has been previously identified by voxel-wise analysis in the inferior-anterior part of the rectum as highly predictive of rectal bleeding (RB) in prostate cancer radiotherapy.

  • Ref: Front Oncol. 2020 Sep 11;10:1597.
  • Année de publication : 2020
  • Auteurs : Lafond C, Barateau A, N'Guessan J, Perichon N, Delaby N, Simon A, Haigron P, Mylona E, Acosta O, de Crevoisier R.
  • Réseaux : Réseaux: « Vectorisation, Imagerie, Radiothérapies »
Lire la publication

Antibody-Drug Conjugates: The Last Decade.

An armed antibody (antibody-drug conjugate or ADC) is a vectorized chemotherapy, which results from the grafting of a cytotoxic agent onto a monoclonal antibody via a judiciously constructed spacer arm. ADCs have made considerable progress in 10 years.

  • Ref: Pharmaceuticals (Basel). 2020 Sep 14;13(9):245.
  • Année de publication : 2020
  • Auteurs : Joubert N, Beck A, Dumontet C, Denevault-Sabourin C.
  • Réseaux : Réseaux: « Vectorisation, Imagerie, Radiothérapies »
Lire la publication

γ9δ2T cell diversity and the receptor interface with tumor cells.

γ9δ2T cells play a major role in cancer immune surveillance, yet the clinical translation of their in vitro promise remains challenging.

  • Ref: J Clin Invest. 2020 Sep 1;130(9):4637-4651.
  • Année de publication : 2020
  • Auteurs : Vyborova A, Beringer DX, Fasci D, Karaiskaki F, van Diest E, Kramer L, de Haas A, Sanders J, Janssen A, Straetemans T, Olive D, Leusen J, Boutin L, Nedellec S, Schwartz SL, Wester MJ, Lidke KA, Scotet E, Lidke DS, Heck AJ, Sebestyen Z, Kuball J.
  • Réseaux : Réseaux: non classé
Lire la publication

Relationship of Tumor Radiation-absorbed Dose to Survival and Response in Hepatocellular Carcinoma Treated with Transarterial Radioembolization…

In humans, histiocytic sarcoma (HS) is an aggressive cancer involving histiocytes. Its rarity and heterogeneity explain that treatment remains a challenge.

  • Ref: Radiology. 2020 Sep;296(3):673-684.
  • Année de publication : 2020
  • Auteurs : Hermann AL, Dieudonné A, Ronot M, Sanchez M, Pereira H, Chatellier G, Garin E, Castera L, Lebtahi R, Vilgrain V; SARAH Trial Group.
  • Réseaux : Réseaux: « Vectorisation, Imagerie, Radiothérapies »
Lire la publication